Sign up
Tech Capital

Telix Pharmaceuticals nearing revenue generation as M&A activity in sector heats up

Telix Pharmaceuticals Ltd. (ASX:TLX) CEO Dr. Christian Behrenbruch updates Proactive Investors on focus and achievements since the company listed on the ASX in November 2017.

Telix is establishing a pipeline of oncology programmes at varying stages of development in multiple international markets, with revenue generation in sight for some of the more advanced projects.

 

View full TLX profile View Profile
View All

© tech Capital 2018

Tech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed tech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Tech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Technology market.